Serum ischemia modified albumin and vascular endothelial growth factor levels following intravitreal bevacizumab injections

European Journal of Ophthalmology
Uri SoibermanAdiel Barak

Abstract

Previous reports have demonstrated that the serum levels of vascular endothelial growth factor (VEGF) are reduced after intravitreal injections of bevacizumab. This study aimed to determine the serum levels of ischemia-modified albumin (IMA), a marker of ischemia, and VEGF following intravitreal injections of bevacizumab. This was a prospective study. Blood samples were drawn prior to injection and at 1, 7, and 30 days after injection. A total of 11 patients participated in this study. Mean serum IMA levels were lower than baseline during follow-up, with statistically significant differences compared to baseline levels at day 1 and day 30 (preinjection: 49.82 ± 15.28 ng/mL; 44.57 ± 12.01 ng/mL, p = 0.007, and 43.71 ± 13.82 ng/mL, p = 0.001, respectively). Mean serum VEGF levels were lower than baseline throughout the follow-up period (from 307.45 ± 273.45 pg/mL at baseline to 159.55 ± 120.68 pg/mL at day 30). Mean serum VEGF levels were significantly lower compared to baseline levels at day 1 and day 7 (147.09 ± 106.08 pg/mL, p = 0.014; 72.91 ± 50 pg/mL, p = 0.011, respectively). In this study, mean serum IMA and VEGF levels were lower following intravitreal bevacizumab injections.

References

Jan 27, 2005·Investigative Ophthalmology & Visual Science·Jacques GaudreaultVanessa Shiu
Apr 13, 2006·Scandinavian Journal of Urology and Nephrology·Robert G HahnLars Sandfeldt
May 1, 2007·Ophthalmology·Sophie J BakriRavinder J Singh
Dec 7, 2007·Ophthalmology·Sophie J BakriRavinder J Singh
Dec 17, 2010·Clinical Biochemistry·Sílvia J PivaRafael N Moresco
Dec 24, 2010·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Zerrin Defne DundarSadik Girisgin
Mar 20, 2012·Translational Research : the Journal of Laboratory and Clinical Medicine·Devin W KehlAlan S Maisel
May 5, 2012·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupFrederick L Ferris
Aug 8, 2012·Clinical Chemistry and Laboratory Medicine : CCLM·Said Sami ErdemMehmet Gül
Dec 5, 2012·Gynecologic Oncology·Bozena DobrzyckaSlawomir Jerzy Terlikowski

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

CATT
SPSS

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.